Sainos Medical

Sainos Medical Science and Technology Co., Ltd. was founded by Dr. Sun Jianhua in 2007 in Tianjin Economic-Technological Development Area, with a registered capital of RMB 360 million, focusing on research, development, production and sales of high-end interventional medical devices.
The company has built an internationally first-class R&D and production platform, covering over 5,000 square meters of R&D and production space, of which 2,000 square meters is a Class 10,000 clean room. The R&D and production base operates in accordance with international medical device standards and was selected as a 'Tianjin Key Laboratory' in 2012, and a 'Tianjin Enterprise Technology Center' in 2013. The company possesses a complete drug-eluting stent production line and full production capabilities for balloon catheters, bare metal stents, and drug coatings, with an annual production capacity of 200,000 drug-eluting stent systems. The high-end interventional medical device R&D and transformation center established by the company covers key areas of interventional therapy, including coronary arteries, heart valves, intracranial, and peripheral vascular diseases.
Since its inception, the company has received various recognitions: in 2009 it was certified as '* High-tech Enterprise', in 2010 it was named one of 'China's 100 Most Promising Startups by Returned Overseas Students', in 2014 it won the 'Sino-French Team Collaboration' Innovation Award, in 2016 it received the 'International Cooperation • Belt and Road Interventional Training Best Support Award' from the China Cardiovascular Health Alliance, and in 2016 the 'AAA Credit Enterprise' in the Ministry of Commerce's enterprise credit evaluation.
The company emphasizes people-centric management and currently has over 400 employees both at home and abroad, among whom 51 are R&D personnel and 26 hold master's degrees or above. It has established a multi-disciplinary professional technical team with rich experience in product development, trial production, and clinical affairs. Meanwhile, it has built a marketing team mostly composed of personnel with medical backgrounds and years of experience in sales in this field. Currently, the key leaders and personnel in critical positions in R&D, quality, marketing, sales, and other departments come from Fortune Global 500 companies within the industry, laying a foundation for the company's internationalization.
The company emphasizes innovation and has obtained 169 authorized patents (including 158 invention patents, 10 utility model patents, and 1 design patent), with 98 patents pending approval. PCT international patent protection covers more than ten countries.
The company emphasizes internationalization and has established subsidiaries in Hong Kong, the United States, Japan, and the Netherlands. It is currently conducting a global series of clinical studies (PIONEER study) covering major markets such as the United States, Japan, Europe, and China, making it the first Chinese coronary stent company to be approved to conduct clinical trials in the United States and Japan.
The company's main product, the BuMA® bioabsorbable drug-eluting coronary stent system, received CFDA product approval in December 2010 and has since been awarded honors such as 'Sino-French Team Collaboration Innovation Product Award', 'National Key New Product', 'Top Ten Major Medical and Health Achievements', 'Tianjin Trumps Product', and 'First Prize in Tianjin Science and Technology Progress'. This product has been used in 900 hospitals in China, holding a 12% market share in domestic coronary stents. The product is also sold to Thailand, Indonesia, South Korea, Brazil, Kazakhstan, and other countries. The cumulative global implantation volume exceeds 500,000 units.
In the next 3-5 years, the company plans to launch multiple products with headline-level quality in areas such as coronary heart disease, vascular disease, and heart valve disease, and to achieve the goal of entering developed-country markets. Relying on its existing technological advantages and global intellectual property layout, it aims to fully realize internationalization in technological innovation and marketing, and establish a high-end corporate brand image.
We will uphold the concept of 'Technology Empowers Health' and strive to fulfill the company's mission: through continuous innovation, we provide safe, effective, and high-quality products, enabling more patients to benefit from advances in modern medical science, saving more lives, and improving people's quality of life. We also aim to establish the 'Created in China' brand internationally, thereby contributing our modest efforts to enhancing the technological level of China's medical device industry and to the nation's economic development!